Price target
64.430.000.00%
The 14 analysts offering 1-year price forecasts have a max estimate of — and a min estimate of —.
Analyst rating
Based on 16 analysts giving stock ratings in the past 3 months.
This is not investment advice and doesn't take into account your personal circumstances. It isn't a recommendation to buy, sell, or hold any asset. See the Terms of Use and always do your own research.
Frequently asked questions
Rapport Therapeutics, Inc. reported the following EPS data for the last quarter:
– Actual EPS: −0.84 USD
– Estimate: −1.20 USD → 30.21% surprise
– Next quarter estimate: −0.95 USD
What to check next in Rapport Therapeutics, Inc. financials:
– Revenue: Is growth supporting earnings?
– Margins: Are profits improving efficiently?
– Cash flow: Are earnings backed by real cash?
– Actual EPS: −0.84 USD
– Estimate: −1.20 USD → 30.21% surprise
– Next quarter estimate: −0.95 USD
What to check next in Rapport Therapeutics, Inc. financials:
– Revenue: Is growth supporting earnings?
– Margins: Are profits improving efficiently?
– Cash flow: Are earnings backed by real cash?
Rapport Therapeutics, Inc. is expected to report 7.14 K USD in revenue for the next quarter, based on analyst estimates.
How to read forecasts:
– Compare with previous periods: Identify growth or slowdown trends
– Watch estimate revisions: Changes may signal shifting sentiment
– Check segment expectations: Some business lines may drive growth more than others
What to use alongside:
– Earnings (EPS): Profitability alongside revenue
– Margins: Efficiency and cost control
– Market news: Management outlook and market context
How to read forecasts:
– Compare with previous periods: Identify growth or slowdown trends
– Watch estimate revisions: Changes may signal shifting sentiment
– Check segment expectations: Some business lines may drive growth more than others
What to use alongside:
– Earnings (EPS): Profitability alongside revenue
– Margins: Efficiency and cost control
– Market news: Management outlook and market context
Analysts set the RAPP price target at 64.43 USD, with estimates ranging from 47.00 USD (low) to 89.00 USD (high).
How to read price targets:
– Compare with current price: Shows potential upside or downside
– Watch the spread: A wide range suggests higher uncertainty
– Track revisions: Upgrades/downgrades can signal shifting sentiment
What to use alongside:
– Technical analysis: Trends, support/resistance, momentum
– Fundamentals: Revenue, earnings, margins
– Market news: Events that may impact future price
How to read price targets:
– Compare with current price: Shows potential upside or downside
– Watch the spread: A wide range suggests higher uncertainty
– Track revisions: Upgrades/downgrades can signal shifting sentiment
What to use alongside:
– Technical analysis: Trends, support/resistance, momentum
– Fundamentals: Revenue, earnings, margins
– Market news: Events that may impact future price
Rapport Therapeutics, Inc. is currently rated "Strong buy" based on the opinions of 16 analysts over the past 3 months.
How to read analyst ratings:
– Check distribution: Buy vs Hold vs Sell recommendations
– Compare with price targets: Understand expected upside/downside
– Account for diverse opinions: Not all analysts agree — breakdown matters
Go further with your analysis:
– Open the Fundamentals graphs to chart key financial metrics and analyze trends over time
– Use the Stock Screener to compare across the market and find similar opportunities
– Follow market news to understand what’s driving sentiment and price moves
How to read analyst ratings:
– Check distribution: Buy vs Hold vs Sell recommendations
– Compare with price targets: Understand expected upside/downside
– Account for diverse opinions: Not all analysts agree — breakdown matters
Go further with your analysis:
– Open the Fundamentals graphs to chart key financial metrics and analyze trends over time
– Use the Stock Screener to compare across the market and find similar opportunities
– Follow market news to understand what’s driving sentiment and price moves